Bioshares

Delivering independent investment research to investors on Australian biotech, pharma and healthcare companies.

The Bioshares Advantage

Bioshares is an investment report tailored to needs of biotech and healthcare investors. It is delivered electronically each week. That means **you are kept up to date**.

Bioshares is not wishy-washy. We are independent. We tell investors whether to buy, sell or hold a stock. You're not left confused by new-fangled broker gobbledegook. You get our opinion, delivered fairly and squarely.

You get the **best written**, **most readable**, **most consistent** biotech research produced in Australia.

Can you get more coverage of biotech and healthcare stocks than in Bioshares? We don't think so. Bioshares **covers around 70 of the 145 companies** listed in the Bioshares Index.

Bioshares doesn't paint itself into a corner when it comes to biotech investing. What happens? **We educate. We inform. You learn. You stay ahead. You make money**. We aim to get you in and out of stocks before the crowd comes along.

Subscription Rates (inc. GST)

24 issues per year (electronic distribution): **$550**

For multiple email distributions within the same business cost centre, our pricing structure is as follows:

$ 900	2-3 email addresses
$1200	4-5 email addresses
$1500	6-10 email addresses

To subscribe, post this subscription form to:

Bioshares
PO Box 193 Richmond VIC 3121

I enclose a cheque for **$** made payable to **Blake Industry & Market Analysis Pty Ltd**, or

Please charge my credit card **$** MasterCard ☐ Visa ☐

Card Number ☐☐☐☐ ☐☐☐☐ ☐☐☐☐ ☐☐☐☐

Signature _____ Expiry date _____

Subscriber details

Name _____

Organisation _____

Ph ( ) _____

Email (must be completed) _____

Enquiries Ph: *(0403 850 425)* Email: *info@bioshares.com.au*

Bioshares is published by Blake Industry and Market Analysis Pty Ltd ABN 47 085 334 292
AFS Licence No 258032

The information provided in Bioshares, including general investment advice, is provided only for receipt and use in Australia and New Zealand, for subscribers to Bioshares, who are Australian or New Zealand citizens or commercial entities.